56(10): 2188-2205. 除了靶向PD-1和PD-L1的ICIs外，其他检查点分子，例如：LAG3、TIGIT、TIM3、VISTA等；效应T细胞活性增加可通过过继性转移细胞治疗或使用T ...

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...

GSK and iTeos anti-TIGIT antibody belrestotug showed efficacy in a phase 2 trial in PD-L1-positive non-small cell lung cancer (NSCLC), providing some much-needed positive news for the beleaguered ...

Having said that, it is because this company made a move about a month ago to receive ex-China development and commercial rights to ImmuneOnco's PD-L1/VEGF bispecific antibody known as IMM2510 ...

More than two years after an initial FDA approval in melanoma, Bristol Myers Squibb is moving its PD-1/LAG-3 combo Opdualag ...

The rate is also almost double the discontinuation rates reported for Roche's TIGIT/PD-L1 combo of tiragolumab and Tecentriq in the same setting, Leerink Partners said. To cut down on unnecessary ...

The most advanced product candidate being worked on by ITOS is belrestotug, an anti-TIGIT antibody that the ... in patients with advanced, PD-L1-high non-small cell lung cancer (NSCLC).

As a numerical comparison, Keytruda monotherapy achieved a 45% ORR in first-line PD-L1 high patients ... drug conjugates and bispecific antibodies. "ESMO 2024: TIGIT race tightens with first ...

Opens in a new tab or window Ivonescimab -- a novel first-in-class PD-1/VEGF bispecific antibody -- led ... as first-line therapy for PD-L1-positive, advanced non-small cell lung cancer (NSCLC ...